‘From missing in action to back in action’
OSSIO’s new approach to bunionectomy features beveled threaded trimmable fixation nails and streamlined instrument set to ensure perfect fit for each patient’s bio-integrative, metal-free repair
TAMPA, Fla.–(BUSINESS WIRE)–#medicaldevice–With the launch today of OSSIOfiber® Minimally Invasive All-natural (MIA) Bunion Correction System, OSSIO Inc. — a fast-growing medical technology company focused on advancing orthopedic surgery with bio-integrative, metal-free fixation implants — takes a major step forward in perfecting bunionectomy for surgeons and patients and significantly expands its footprint in a fast-growing multimillion-dollar industry.
As with all OSSIOfiber implants, the 4.5x70mm beveled threaded trimmable fixation nail in OSSIO’s new bunionectomy system goes MIA — missing in action — after fulfilling its fixation function, which typically takes about two years. As the bone heals, the metal-free, bio-integrative implant becomes part of the patient’s native anatomy, leaving nothing permanent behind but a strong stable bone — restored, regrown, renewed.
Showcased for the first time this week at the annual conference of the American College of Foot and Ankle Surgery (ACFAS) in Las Vegas, the company’s new bunionectomy system also features a streamlined and efficient instrument set, including the implant designed for intraoperative trimming and sharpening to ensure a custom fit for each patient’s unique anatomy.
Steven K. Neufeld, M.D., founder of the Orthopaedic Foot & Ankle Center in Falls Church, Va., performed one of the first bunionectomies with the new system from OSSIO: “For my patients who need a bunionectomy, I offer treatment with the OSSIOfiber MIA Bunion Correction System,” Dr. Neufeld, an orthopedic surgeon specializing in minimally invasive surgical techniques, said. “This approach represents the pinnacle of minimally invasive foot and ankle surgery and signifies a significant advance in bio-integrative bunion repair. That’s how you elevate outcomes!”
Dr. Neufeld published the first U.S.-based study on minimally invasive bunion surgery, “Outcomes and Surgical Strategies of Minimally Invasive Chevron/Akin Procedures” (Foot & Ankle International, June 2021).
“Importantly, my medical research and clinical outcomes are closely aligned, which inspires confidence among the thousands of bunionectomy practitioners nationwide,” he explained. “Our 100-plus study cases demonstrated the efficacy of minimally invasive techniques in achieving excellent radiographic corrections with low complication rates. Incorporating OSSIOfiber implants into my contemporary practice elevates these outcomes further by eliminating the need for permanent metal hardware, reducing risks like tissue irritation and removal surgeries and promoting a more natural healing process that patients truly appreciate.”
Dr. Neufeld recently presented a case series titled “Clinical and Radiographic Outcome of Biointegrative Minimally Invasive Bunion Surgery,” (MIFAS 7th International Conference, November 2025) that evaluated the use of OSSIOfiber bio-integrative implants. This study highlights how bio-integrative implants provide secure fixation that is gradually replaced by natural bone and preserves the natural landscape.
In a group of eighteen patients (average age 60), the OSSIOfiber MIA procedures resulted in significant corrections. Notably, patients returned to normal activity within six weeks, with confirmed osseous union by the 26-week mark and no hardware removal or revisions reported. These findings suggest that bio-integrative implants effectively mitigate metal-related complications in minimally invasive bunion surgery.
The OSSIOfiber® Threaded Trimmable Fixation Nails are indicated for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis and bone grafts of the upper extremity, fibula, knee, ankle and foot in the presence of appropriate brace and/or immobilization in adults and children (2–12 years) and adolescents (12–21 years) in which growth plates have fused or in which growth plates will not be crossed by fixation.
“Our new OSSIOfiber® Minimally Invasive All-natural (MIA) Bunion Correction System gives the acronym a double meaning,” OSSIO CEO Brian Verrier explained. “The patient’s bunion goes missing, just like the implant itself. After the metal-free nail vanishes through bio-integration, patients go from missing in action to back in action. They walk away with their natural anatomy intact and no concerns about metal left in their body.”
“It’s a real transformation in how bunion surgery feels and performs and represents the future of intelligent, patient-centered orthopedic healing,” Verrier added.
According to MedlinePlus, a service of the National Institutes of Health, “A bunion, known technically as hallux valgus, is a bony bump on the side of the foot at the base of the big toe. Bunions develop slowly as pressure on the joint at the base of the big toe causes the toe to move out of place, leaning inward toward the second toe. Because this joint carries a lot of weight during activities like standing and walking, bunions can cause foot pain, stiffness, redness and swelling.”
[Without treatment], MedlinePlus explains, “bunions get worse over time…. They are a very common foot disorder, affecting about a third of adults in the United States … and are more common in women than in men, likely because of differences in foot anatomy, footwear [choices] and genetic influences. The prevalence of bunions increases with age.”
About OSSIOfiber implants
Based on Intelligent Bone Regeneration Technology, OSSIOfiber implants combine unparalleled mechanical strength and natural healing in a bio-integrative, metal-free design. Their proprietary mineral fiber matrix enables rapid bone in-growth, regeneration and replacement — a new way for orthopedic surgeons to restore their patients’ stability and mobility while leaving nothing permanent behind.
OSSIOfiber implants represent the first credible alternative to metal, absorbable and allograft fixation devices. The most significant advance in orthopedic fixation technology in more than 100 years, this novel medical technology has the potential to address an increasingly wide array of surgical applications due to the proprietary “know-how” to manufacture limitless implant platforms. Looking ahead, the company intends to continue developing additional applications for OSSIOfiber implants in all major segments of orthopedics.
Notably for U.S. healthcare providers and payors, OSSIOfiber implants utilize existing reimbursement codes and surgical techniques. Their uptake continues to grow because of strong patient and surgeon preference to avoid the concerns and complications of metal fixation implants. Through January 2026, more than 75,000 OSSIOfiber implants have been used to treat orthopedic patients in the U.S.
About OSSIO
OSSIO is an orthopedic medical technology company committed to transforming the surgical experience for patients, physicians, providers and payors. Founded in 2014, the company’s vision is to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology.
OSSIO conducts product development in Caesarea, Israel, and commercial operations in Palmetto, Fla., and Woburn, Mass. For more information about the company and OSSIOfiber implants, visit www.ossio.io.
Disclaimer: Forward-looking statements in this news release are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict.
Contacts
Joe McGrath
Scope Strategic Communications
[email protected]
+1 612 819 6421
